

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number  
**WO 02/39989 A1**

(51) International Patent Classification<sup>7</sup>: A61K 31/00,  
31/496, A61P 29/00, 1/00

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,  
ZA, ZW.

(21) International Application Number: PCT/EP01/12686

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(22) International Filing Date:  
2 November 2001 (02.11.2001)

(25) Filing Language: English

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(26) Publication Language: English

(30) Priority Data:  
00125409.3 20 November 2000 (20.11.2000) EP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARTOSZYK, Gerd** [DE/DE]; Kreuzstrasse 57, 64331 Weiterstadt (DE). **SEDMAN, Ewen** [GB/GB]; The Barley House, Dene Lea, Ropley, Alresford, Hampshire SO24 0BH (GB).

(74) Common Representative: **MERCK PATENT GMBH**; Frankfurter Strasse 250, 64293 Darmstadt (DE).



A1

WO 02/39989

(54) Title: NOVEL USE OF COMBINED 5-HT<sub>1A</sub> AGONISTS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS

(57) Abstract: The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain, as well as for the treatment of irritable bowel syndrome (IBS).

**Novel use of combined 5-HT<sub>1A</sub> agonists and selective serotonin  
reuptake inhibitors**

5       The present invention relates to the use of compounds being combined  
selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor  
agonists for the manufacture of a medicament for the treatment of chronic  
pain.

10      Particularly, the present invention relates to the use of combined selective  
serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists  
chosen from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-  
carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt  
thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-  
carbonitrile or a physiologically acceptable salt thereof, for the manufacture  
15     of a medicament for the treatment of chronic pain.

20      1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine,  
physiologically acceptable salts thereof (US 5,532,241, column 7, lines 30  
to 58) and a process (US 5,532,241, Example 4) by which it/they can be  
prepared are known from U.S. Patent US 5,532,241. The compound which  
is referred to herein is described in the patent as a combined selective  
serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist.  
Therefore, the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-  
benzofuran-5-yl)-piperazine and its physiologically acceptable acid addition  
25     salts for the manufacture of a medicament for the treatment of depressive  
disorders, including the sub-type disorders major depressive disorder and  
dysthymic disorder, for the treatment of anxiety disorders, for the treatment  
of psychiatric disorders like psychoses, schizophrenia or schizoaffective  
disorder, for the treatment of cerebral infarct like stroke and cerebral  
30     ischemia, for the treatment of CNS disorders such as tension, for the  
therapy of side-effects in the treatment of hypertension (e.g. with  $\alpha$ -

methyldopa) and for the prophylaxis and therapy of cerebral disorders is disclosed. Additionally, the use in endocrinology and gynecology is described, e.g. for the treatment of acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome or undesired puerperal lactation.

5

3-{4-[4-(4-Cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile, physiologically acceptable salts thereof (EP 0 736 525, page 3, lines 5, 26 and, page 8 lines 28 to page 9 lines 12) and a process (EP 0 736 525, Example 1) by which it/they can be prepared are known from EP 0 736 525. They show, in particular, actions on the central nervous system, especially 5-HT<sub>1A</sub>-agonistic and 5-HT-reuptake inhibiting actions. Therefore they are suitable for the treatment of disorders of the central nervous system such as states of tension, depressions and/or psychoses and of side effects in the treatment of hypertension. Additionally, the use in 10 endocrinology and gynecology is described, e.g. for the treatment of acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome or undesired puerperal lactation, and furthermore for the prophylaxis and therapy of cerebral disorders, in particular in geriatrics, similarly to certain ergot alkaloids and for the control of the sequelae of 15 cerebral infarcts (apoplexia cerebri), such as stroke and cerebral ischaemias.

The invention had the object of providing novel uses for compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-

25 HT<sub>1A</sub> receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof.

30 It has been found that combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a

physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, also have activity against pain, especially against chronic pain.

5

Piperazines, such as 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable acid addition salts, are disclosed in U.S. Patent US 5,532,241 having analgesic effects. However, the usefulness of such piperazines for the treatment of pain, especially for chronic pain has not been disclosed.

10 The disclosed analgesic effects do not inevitably lead to effective treatments for chronic pain. Acute pain is a normal sensation triggered in the nervous system to alert an individual to possible injury. Chronic pain results from persistent pain signals in the nervous system which continue after the initial damage or injury has disappeared. Chronic pain can occur in the absence of any past injury or evidence of body damage, so-called psychogenic pain.

15 20 As used herein the term pain shall refer to all types of pain. Preferably, the term shall refer to all types of chronic pain including nociceptive, neuropathic, psychogenic pain, and mixed category pain (nociceptive and neuropathic components). This in particular includes, but is not limited to, diabetic neuropathy, neurogenic pain, central pain, somatic pain, visceral and cancer pain, inflammatory pain, post-operative pain, chronic low back pain, sciatica, cervical and lumbar pain, tension headaches, cluster headaches, chronic daily headaches, herpes neuralgia and post-herpetic neuralgia, facial and oral neuralgias and myofascial pain syndromes, phantom limb pain, stump pain and paraplegic pain, dental pain, opioid resistant pain, post-surgical pain including cardiac surgery and mastectomy, pain of labour and delivery, post-partum pain, post-stroke pain, angina pain, genitourinary tract pain including pelvic pain and cystitis and vulvar

25

30

vestibulitis and orchialgia, irritable bowel syndrome, pre-menstrual syndrome pain, pain resulting from burns or chemical injury or sunburn, and bone injury pain.

- 5 Sub-types of nociceptive pain are somatic pain and visceral pain. Somatic pain includes inflammatory pain, post-operative pain, chronic low back pain, cervical and lumbar pain, cluster headaches, dental pain, pain of labour and delivery, post-partum pain, pain resulting from burns or chemical injury or sunburn, and bone injury pain. Visceral pain includes
- 10 cancer pain, post-surgical pain including cardiac surgery, angina pain, genito-urinary tract pain including pelvic pain and cystitis and vulvar vestibulitis and orchialgia and pre-menstrual pain syndrome. Sub-types of neuropathic pain are diabetic neuropathy, cancer pain, neurogenic pain, central pain, sciatica, herpes neuralgia, post-herpetic neuralgia, facial and
- 15 oral neuralgias, phantom limb pain, stump pain and paraplegic pain, opioid-resistant pain, post-surgical pain including mastectomy and post-stroke pain. Sub-types of psychogenic pain are chronic daily headaches and tension headaches. Sub-types of mixed category pain are cancer pain, myofascial syndromes and tension headaches (e.g. McCaffery M, Pasero
- 20 C. Pain:Clinical Manual p19 St. Louis: Mosby 1999; Merske H and Bogduk (eds) Classification of chronic pain, second edition, IASP Task Force on Taxonomy, p 209-214, IASP Press, Seattle 1994 ; The Merck Manual, Section 14, Chapter 167, Pain, 17<sup>th</sup> Edition Merck & Co 1999).
- 25 The effectiveness of selective serotonin reuptake inhibitors (SSRIs) in various pain indications has been demonstrated in animals as well as humans.
- For example, SSRIs have been shown to enhance the effects of traditional
- 30 opioid analgesics and to be effective themselves against acute pain, inflammatory pain, and neuropathic pain in various animal models (e.g. Messing et al., Psychopharmacol. Commun. 1975, 1: 511-521; Hynes et

al., Life Sci. 1985, 36: 2317-2323; Larsen and Arnt, Acta Pharmacol Toxicol. Copenh. 1985, 57: 345-351; Larsen and Hyttel, Acta Pharmacol Toxicol. Copenh. 1985, 57: 214-218; Yamamoto et al., Nippon Yakurigaku Zasshi 1989, 94: 189-206; Fasmer et al., Neuropharmacology 1989, 28: 5 1363-1366; Ardid et al., Fundam. Clin. Pharmacol. 1992, 6: 75-82; Akunne and Soliman, Pharmacol. Biochem. Behav. 1994, 48: 411-416; e.g. Schreiber et al., Eur. Neuropsychopharmacol. 1996, 6: 281-284; Korzeniewska et al., Pharmacol. Biochem. Behav. 1998, 59: 331-338; Luger et al., Pharmacol. Toxicol. 1999, 85: 263-268; Sawynok et al., Pain 10 1999, 82: 149-158; McCleane, Pain 2000, 85: 311-312).

SSRIs are also effective in experimental pain in healthy volunteers (Coquoz et al., Schweiz. Med. Wochenschr. 1991, 121: 1843-1845; Coquoz et al., Clin. Pharmacol. Ther. 1993, 54: 339-344) and, more relevant, in patients 15 suffering of various chronic pain conditions like headache (tension headache), diabetic neuropathy, idiopathic pain, low back pain, phantom limb pain, rheumatic pain, irritable bowel syndrome, premenstrual syndrome pain or generalized or mixed pain syndrome (e.g. radicular pain, atypical facial pain) (e.g. Theesen and Marsh, DICP 1989, 23: 572-574; 20 Sindrup et al., Pain 1990, 42: 135-144; Sindrup et al., Ther. Drug Monit. 1991, 13: 408-414; Petitto et al., Psychosomatics 1992, 33: 338-341; Boyer, Int. Clin. Psychopharmacol. 1992, 6 (suppl. 5); 5-12; Power-Smith and Turkington, Br. J. Psychiatry 1993, 163: 105-106; Manna et al., Headache 1994, 34: 44-49; Langemark and Olesen, Headache 1994, 34: 25 20-24; Finley, Ann. Pharmacother. 1994; 28: 1359-1369; Saper et al., Headache 1994, 34: 497-502; Gruber et al., Psychiatr. Clin. North Am. 1996, 19: 351-369; Rani et al., Aneth. Analg. 1966, 83: 371-375; McQuay et al., Pain 1996, 68: 217-227; Jung et al., J. Gen. Intern. Med. 1997, 12: 384-389; Abramson and Garfin, Pain 1999, 83: 137-145; Baraczka et al., 30 Orv. Hetil. 1997, 138: 2605-2607; O'Mally et al., J. Fam. Pract. 1999, 48: 980-990; Ciaramella et al., Minerva Anestesiol. 2000, 66: 55-61; Ansari, Harv. Rev. Psychiatry 2000, 7: 257-277).

Moreover, SSRIs are the most frequent drugs used in depressive disorders, and there is a high comorbidity for depression and pain, and they may even share a common etiology (e.g. Ekselius et al., Scand. J. Rehabil. Med. 1997, 29: 91-96; Max et al., N. Engl. J. Med. 1992, 326: 1250-1256; Gruber et al., Psychiatr. Clin. North Am. 1996, 19: 351-369).

Finally, selective serotonin 5-HT<sub>1A</sub> receptor agonists reduce pain in animals in acute and chronic pain and inflammatory pain models (e.g. Fasmer et al., Pharmacol. Biochem Behav. 1986, 25: 883-888; Bragin et al., Pain 1989, 36: 257-261; Giordano and Rogers, Pain 1989, 39: 109-113; Murphy and Zemlan, Neuropharmacology 1990, 29: 463-468; Crisp et al., Gen. Pharmacol. 1991, 22: 247-251; Danzebrink and Gebhart, Brain Res. 1991, 538: 64-75; Eide and Hole, Neuropharmacology 1991, 30: 727-731; Giordano and Rogers, Pain 1992, 50: 365-372; Mjellem et al., Neuroreport 1992, 3: 1061-1064; Eide and Hole, Cephalgia 1993, 13: 75-85; Korneyev and Seredenin, Life Sci. 1993, 52: 997-1004; Cervo et al., Eur. J. Pharmacol. 1994, 263: 187-191; Xu et al., J. Pharmacol. Exp. Ther. 1994, 269: 1182-1189; Sanchez et al., Neuroreport 1995, 6: 2585-2588; Millan et al., Behav. Brain Res. 1996, 73: 69-77; Robles et al., Eur. J. Pharmacol. 1996, 295: 181-188; Galeotti et al., Pharmacol. Biochem. Behav. 1997, 57: 835-841; Rouzade et al., Digest. Dis. Sci. 1998, 43: 2048-2054; Jain and Kulkarni, Meth. Find. Exp. Clin. Pharmacol. 1999, 21: 161-165; Shannon and Lutz, Psychopharmacology 2000, 149: 93-97). To our knowledge, clinical results in pain patients are not available due to the lack of selective 5-HT<sub>1A</sub> agonists on the market.

Therefore, the combination of serotonin reuptake inhibiting properties and serotonin 5-HT<sub>1A</sub> agonistic properties as realized in 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its salts thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile and its salts thereof represents an advantage over SSRIs alone for the

treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain.

- 5 Accordingly, the present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists for the manufacture of a medicament for the treatment of chronic pain.
- 10 Accordingly, the present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain.
- 15 The present invention relates furthermore to the use of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain.
- 20 A preferred salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.  
Therefore the invention relates to the use for the manufacture of a medicament for the treatment of chronic pain in which the
- 25 pharmacologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
- 30 A preferred salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

Therefore the invention relates to the use for the manufacture of a medicament for the treatment of chronic pain in which the pharmacologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

Additionally, the invention relates to the use of a pharmaceutical composition containing at least a compound being a combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of chronic pain.

15

Thus the invention provides a pharmaceutical preparation for the treatment of pain characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.

20

Thus the invention provides a pharmaceutical preparation for the treatment of pain characterized in that it contains at least 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or one of its pharmaceutically acceptable salts.

25

The compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of pain (e.g. duloxetine). A unit dose will generally contain from 0.1 to 1000 mg, preferably between approximately 0.1 and 500 mg, in particular 5, 10, 20, 30, 40, 50, 100, 150, 200, 250 and 300 mg. The composition may be administered once or more

times a day for example 2, 3 or 4 times daily. The daily dose is preferably between approximately 0.01 and 50 mg/kg of body weight. However, the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body

5 weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred, but also peroral routes of administration (e.g. intravenous or transdermal) can be utilized.

10

It is preferred that the chronic pain to be treated by combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, is nociceptive pain. Preferred indications of nociceptive pain are inflammatory and post-operative pain.

20

Therefore, the invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of nociceptive pain.

25

It is preferred that the chronic pain to be treated by combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically

30

acceptable salt thereof, is neuropathic pain. Preferred indications of neuropathic pain are neurogenic pain and facial and oral neuralgias.

Therefore, the invention relates to the use of compounds being combined  
5 selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a  
10 physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of neuropathic pain.

It has additionally been found that combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a  
15 physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, are further useful in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain. A preferred  
20 indication is irritable bowel syndrome.

Irritable bowel syndrome (IBS) is a common disorder of the intestines that leads to crampy pain, gassiness, bloating, and changes in bowel habits. The cause of IBS is not known but it often has been thought to be caused  
25 by emotional conflict or stress. IBS is called a functional disorder because there is no sign of disease when the colon is examined. People suffering from IBS usually have crampy abdominal pain with painful constipation or diarrhea.

30 Therefore, the invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-

benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of inflammatory bowel syndrome.

5

A preferred salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

Therefore the invention relates to the use for the manufacture of a  
10 medicament for the treatment of irritable bowel syndrome in which the pharmacologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

15 A preferred salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

Therefore the invention relates to the use for the manufacture of a  
medicament for the treatment of irritable bowel syndrome in which the  
20 pharmacologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

25 Additionally, the invention relates to the use of a pharmaceutical composition containing at least a compound being a combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically  
30 acceptable salt thereof, together with at least one solid, liquid or semiliquid excipient or adjunct for the treatment of irritable bowel syndrome.

Thus the invention provides a pharmaceutical preparation for the treatment of irritable bowel syndrome characterized in that it contains at least 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or one of its pharmaceutically acceptable salts.

5

Thus the invention provides a pharmaceutical preparation for the treatment of irritable bowel syndrome characterized in that it contains 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or one of its pharmaceutically acceptable salts.

10

The compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists according to the invention are preferably administered in analogy to other known commercially available preparations for the treatment of irritable bowel syndrome (IBS). A unit dose will generally contain from 0.1 to 1000 mg, preferably between approximately 0.1 and 50 mg, in particular 5, 10 and 20 mg. The composition may be administered once a day. The daily dose is preferably between approximately 0.01 and 10 mg/kg of body weight.

15

However, the specific dose for each patient depends on all sorts of factors, for example on the activity of the specific compound employed, on the age, body weight, general state of health, sex, on the diet, on the time and route of administration, on the excretion rate, pharmaceutical substance combination and severity of the particular disorder to which the therapy relates. Oral administration is preferred, but also peroral routes of administration (e.g. intraveneous or transdermal) can be utilized.

20

The pharmaceutical preparations used for the treatment of pain or preferred for IBS, can be used as pharmaceuticals in human or veterinary medicine.

25

A process for the manufacture of a pharmaceutical preparation used for the treatment of chronic pain is characterised in that one compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub>

30

receptor agonist chosen from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-[4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl]-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, are  
5 converted into a suitable dosage form together with at least one solid, liquid or semiliquid excipient or adjunct.

Suitable excipients are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical administration and which do not react with 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-  
10 piperazine and/or one of its biocompatible salts, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatine, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Forms which are used for oral administration are, in particular, tablets, pills, sugar-coated tablets,  
15 capsules, powders, granules, syrups, liquids or drops, forms for rectal administration are, in particular suppositories, forms for parenteral administration are, in particular, solvents, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants, and forms for topical administration are transdermal plasters, ointments, creams or  
20 powders. 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and/or one of its pharmaceutically acceptable salts may also be lyophilized and the resulting lyophilisates used for example for the preparation of injectable products. The abovementioned preparations can be in sterilized form and/or comprise auxiliaries such as glidants,  
25 preservatives, stabilizers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colourings, flavourings and/or other active ingredients, e.g. one or more vitamins.  
Preparations may, if desired, be designed to give slow release of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a  
30 biocompatible salt thereof.

The following examples relate to animal models which are useful for illustrating the effectiveness of combined 5-HT<sub>1A</sub> agonists and serotonin reuptake inhibitors.

- 5       Example 1: Procedures in the mouse and the rat to test pain-relieving acute analgetic properties
1. Hot plate test in mouse or rat according to Eddy and Leimbach (J. Pharmacol. Exp. Ther. 1953, 107: 385-393):

10      Mice or rats are placed onto a hot metal plate maintained at 54°C for mice or 52°C for rats surrounded by a Plexiglas cylinder (Height: 13 cm; Diameter: 19 cm). The latency to the first foot-lick is measured (maximum : 30 seconds).

15      2. Tail flick test in mouse or rat according to D'Amour and Smith (J. Pharmacol. Exp. Ther. 1941, 72: 74-79):  
The animal 's tail is heated by means of a thermal light source. The latency before the animal withdraws its tail is measured (maximum: 15 seconds for mice, 30 seconds for rats).

20      20     3. Shock sensitivity test in the mouse or rat follows that described by Eschalier et al. (Eur. J. Pharmacol. 1981, 74: 1-7):  
Each animal is placed on a grid floor connected to an electric shock generator that transmits a brief electric shock to the animal's paws. Three shocks are given at an intensity of 1 mA, each for a duration of 0.5 sec.  
25      The shocks are spaced at 30 second intervals. Response to electric shock is quantified using a scale incorporating three parameters: jump, vocalization and flight (each parameter is scored 0, 1 or 2). The total score obtained for all three parameters for the three shocks is taken as a  
30      measure of sensitivity to electric shock.

4. Shock Titration Test in the rat according to Weiss and Laties (J. Pharmacol. Exp. Ther. 1961, 131: 120-129):

5

10

15

20

25

30

The apparatus consists of a sound-attenuated standard Skinner Box (23 x 21 x 18 cm) fitted with a house light, one lever and a grid floor connected to a programmable scrambled shock generator (Imetronic). The Skinner boxes are connected to a MED.PC programming system which controls the experiment and collected the data automatically. The rats are first trained to press a lever in the experimental chamber in order to stop an electric foot-shock (0.8 mA) administered at 5 second intervals (escape training).

5 They are then trained to control the intensity of the electric shock (30 graded steps: 0.03-0.9 mA) by pressing the lever. When the rat presses the lever in the presence of shock, the shock terminates and returns 5 seconds later at the next lower intensity. If the rat fails to respond during the shock presentation, the shock terminates automatically after 5 seconds and returns 5 seconds later at the next higher intensity (shock titration). Lever pressing between shocks (inter-trial responses) is without consequence.

10 Each training sessions lasts 15 minutes and begins at the tenth intensity level (0.3 mA). The animals receive a administration of the vehicle of the test compound 60 minutes before each session. Two behavioral measures are taken: The median shock level (nociceptive threshold) per rat is defined as the intensity above and below which the animal receives 50% of its

15 shocks, and the Inter-trial responses defined as the number of lever-presses occurring between shock presentations. Drug testing is performed on animals having reached stable baseline performance over two consecutive weeks. Drug testing sessions are given twice weekly with at least one training session without drugs between drug test sessions.

20

25 Animals are tested (training and test sessions) 5 days per week (Monday to Friday). As above, sessions terminate after 15 minutes. Each animal is used as its own control and receives all the selected treatments and controls (vehicle) in separate testing sessions. The sequence of treatments is determined by a procedure to ensure even distribution of the different

30 treatments in time. Each animal is always tested in the same Skinner Box, in the same order and at the same time of the day.

5. Phenylbenzoquinone and acetic writhing tests in mice follow the methods described by Hendershot et al (J. Pharmacol. Exp. Ther. 1959, 125: 237-240):

5 Mice are injected with phenylbenzoquinone (PBQ) (1.25 mg/kg i.p.) or acetic acid (0.5% i.p.). This treatment induces a recognizable writhing response in control animals. The number of writhes is counted for 10 minutes beginning 5 minutes after injection of PBQ or acetic acid.

10 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride at 30 mg/kg p.o. reduced writhes by 82%.

Example 2: Procedures in the mouse and the rat to test pain-relieving properties associated with antiinflammatory processes

15

1. Formalin paw test in the mouse or rat according to Wheeler-Aceto *et al.*, (Psychopharmacology 1991, 104: 35-44):

20 Animals are given an intraplantar injection of 5% formalin (25  $\mu$ l for the mouse, 50  $\mu$ l for the rat) into the posterior left paw. This treatment induces a recognizable flinching response in control animals. The number of flinches is counted for 10 minutes, beginning immediately after injection of formalin (early phase) and again for 5 minutes in mice or 15 minutes in rats, beginning 20 minutes after the injection.

25

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride at 30 mg/kg p.o. reduced the formalin-induced pain response by 79%.

30

Example 3: Procedures in mouse and rat to test pain-relieving properties associated with antiinflammatory processes and antiinflammatory/antipyretic properties

1. Carrageenan Edema Test in the rat follows that described by Winter *et al.* (Proc. Soc. Exp. Biol. Med. 1962, 111: 544-547):

5        Animals are injected with a carrageenan solution into the lower surface of the right hind-paw (0.75 mg per paw in 0.05 ml physiological saline). 2 hours later rats are submitted consecutively to thermal and tactile stimulation of both the non-inflamed and the inflamed hindpaws. For thermal stimulation, the apparatus (Ugo Basile, Reference: 7371) consists of 6 individual Plexiglas boxes (17 x 11 x 13 cm) placed upon an elevated  
10      glass floor. A rat is placed in the box and left free to habituate for 10 minutes. Then, a mobile infrared radiant source (setting 20) is focused under the non-inflamed and inflamed hindpaws and the paw-withdrawal latencies are automatically recorded. Paw-withdrawal interrupts the reflected radiation and switches off the counter and the light source. In  
15      order to prevent tissue damage, if no reaction is noted, the test is terminated after 45 seconds. For tactile stimulation, the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor. The tip of an electronic Von Frey probe is then applied with increasing pressure to the non-inflamed and inflamed hindpaws and the force required to induce  
20      paw-withdrawal is automatically recorded. This procedure is carried out 3 times and the mean force per paw is calculated to provide basic scores per animal. 3.5 hours later, the animals are sacrificed by a blow to the cervical vertebrae and the hind-paws sectioned and weighed. An increase in paw weight (edema) indicates inflammation. This later procedure can also be  
25      applied to mice.

2. Yeast Hyperthermia Test in the mouse or rat according to by Teotino *et al* (J. Med. Chem. 1963, 6: 248):

30      Animals are first measured for rectal temperature using a rectal probe. They are then injected with a yeast suspension (512 mg/kg s.c.). 8 hours later, the test substance is administered. Mice are measured for rectal

temperature immediately before test substance administration and again 60 and 120 minutes later.

Example 4: Procedures in rats to test pain-releaving properties in chronic  
5 pain and inflammation

1. Chronic inflammatory pain test (Freund's adjuvant test) in the rat according to Whiteley (Current Protocols in Pharmacology, Wiley, New York, 5.5, 1999):
- 10 An injection of Freund's adjuvant in rats induces chronic clinical signs of polyarthritis with pain. On Day 1, rats are weighed and injected intradermally with a suspension of *Mycobacterium butyricum* (Freund's adjuvant) into the proximal quarter of the tail (1 mg in 0.1 ml mineral oil). Sham controls receive a similar injection of mineral oil. On Day 18, when 15 the chronic state is fully installed, rats are weighed again and are evaluated for clinical symptoms of inflammation. They are then submitted consecutively to thermal and tactile stimulation of both hindpaws. For the clinical signs, each paw is scored for inflammation according to a 5-point scale (0-4) and the tail according to a 4-point scale (0-3), i.e. a maximum score of 19 per animal. For thermal stimulation, the apparatus (Ugo Basile, Reference: 7371) consists of 6 individual Plexiglas boxes (17 x 11 x 13 cm) placed upon an elevated glass floor. A rat is placed in the box and left free to habituate for 10 minutes. Then, a mobile infrared radiant source (setting 20) is focused under each hindpaw and the paw-withdrawal latency is automatically recorded. Paw-withdrawal interrupts the reflected radiation and switches off the counter and the light source. In order to prevent tissue damage, if no reaction is noted, the test is terminated after 45 seconds. For tactile stimulation, the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor. The tip of an electronic Von Frey probe 25 (Bioseb, Model 1610) is then applied with increasing pressure to each hindpaw and the force required to induce paw-withdrawal is automatically recorded. This procedure is carried out 3 times and the mean force per 30

paw is calculated to provide basic scores per animal. Prior to receiving drug treatment all animals will be submitted to tactile stimulation and assigned to treatment groups matched on the basis of their pain response.

- 5        2. Neuropathic pain test (Chung test) in the rat according to Kim and Chung (Pain 1992, 50: 355-363):  
Tight ligature of spinal nerves in rats is associated with hyperalgesia, allodynia and spontaneous pain, and constitutes therefore a model for peripheral neuropathic pain in humans. Antihyperalgesics reduce these  
10      chronic signs of pain hypersensitivity. Rats (180 - 220 g) are anesthetized (sodium pentobarbital 40 mg/kg i.p.) and an incision at the L4-S2 level is performed to expose the left L5 and L6 spinal nerves. A ligature is tied tightly around each nerve. The wound is then sutured. The rats receive an i.m. injection of 50 000 IU Penicilline and are allowed to recover. At least 2  
15      weeks after the surgery, when the chronic state is fully installed, rats are submitted consecutively to thermal and tactile stimulation of both the non-lesioned and the lesioned hindpaws. For thermal stimulation, the apparatus consists of 6 individual Plexiglas boxes (17 x 11 x 13 cm) placed upon an elevated glass floor. A rat is placed in the box and left free to habituate for  
20      10 minutes. Then, a mobile infrared radiant source (setting 20) is focused under the non-lesioned and lesioned hindpaws and the paw-withdrawal latencies are automatically recorded. Paw-withdrawal interrupts the reflected radiation and switches off the counter and the light source. In order to prevent tissue damage, if no reaction is noted, the test is  
25      terminated after 45 seconds. For tactile stimulation, the animal is placed under an inverted Plexiglas box (17 x 11 x 13 cm) on a grid floor. The tip of an electronic Von Frey probe is then applied with increasing pressure to the non-lesioned and lesioned hindpaws and the force required to induce paw-withdrawal is automatically recorded. This procedure is carried out 3 times  
30      and the mean force per paw is calculated to provide basic scores per animal. Prior to receiving drug treatment all animals will be submitted to

tactile stimulation and assigned to treatment groups matched on the basis of their pain response.

The examples which follow relate to pharmaceutical products:

5

**Example A: Vials**

A solution of 100 g of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist and 5 g of disodium hydrogen phosphate in 3 l of twice-distilled water is brought to pH 6.5 with 2N hydrochloric acid, filter-sterilized, filled into vials, lyophilized under sterile conditions and sealed in sterile form. Each vial comprises 5 mg of active ingredient.

**Example B: Suppositories**

15 A mixture of 20 g of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist is melted with 100 g of soya lecithin and 1400 g of cocoa butter, and the mixture is poured into moulds and left to cool. Each suppository comprises 20 mg of active ingredient.

20

**Example C: Solution**

A solution is prepared from 1 g of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist, 9.38 g of NaH<sub>2</sub>PO<sub>4</sub>·2H<sub>2</sub>O, 28.48 g of Na<sub>2</sub>HPO<sub>4</sub>·12H<sub>2</sub>O and 0.1 g of benzalkonium chloride in 940 ml of twice-distilled water. The pH is brought to 6.8, and the solution is made up to 1 l and sterilized by irradiation. This solution can be used in the form of eyedrops.

30

**Example D: Ointment**

500 mg of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist are mixed with 99.5 g of petroleum jelly under aseptic conditions.

5

**Example E: Tablets**

A mixture of 1 kg of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is tableted in the customary manner in such a way that each tablet comprises 10 mg of active ingredient.

10

**Example F: Sugar-coated tablets**

A mixture is tableted analogously to Example E, and the tablets are subsequently coated in the customary manner with a coating of sucrose, potato starch, talc, tragacanth and colouring.

**Example G: Capsules**

20 2 kg of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist are filled into hard gelatin capsules in the customary manner so that each capsule comprises 20 mg of the active ingredient.

**Example H: Ampoules**

25 A solution of 1 kg of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist in 60 l of twice-distilled water is filter-sterilized, filled into ampoules, lyophilized under sterile conditions and sealed in sterile form. Each ampoule comprises 10 mg of active ingredient.

30

**Example I: Spray for inhalation**

14 g of a compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist are dissolved in 10 l of isotonic NaCl solution, and the solution is filled into commercially available pump-operated spray containers. The solution can be sprayed  
5 into mouth or nose. One actuation (approximately 0.1 ml) corresponds to a dose of approximately 0.14 mg.

10

15

20

25

30

**Patent Claims**

1. Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists for the manufacture of a medicament for the treatment of chronic pain.

5

2. Use according to claim 1 wherein the compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists are selected from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof.

10

3. Use according to claim 2 in which the physiologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

15

20

4. Use according to claim 2 in which the physiologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.

25

5. Pharmaceutical preparation for the treatment of chronic pain characterized in that it contains at least one compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist.

30

6. Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists for the manufacture of a medicament for the treatment of irritable bowel syndrome.

7. Use according to claim 6 wherein the compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT<sub>1A</sub> receptor agonists are selected from the group consisting of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof.
- 5
- 10 8. Use according to claim 7 in which the physiologically acceptable salt of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
- 15 9. Use according to claim 7 in which the physiologically acceptable salt of 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile is 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile hydrochloride.
- 20 10. Pharmaceutical preparation for the treatment of irritable bowel syndrome characterized in that it contains at least one compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT<sub>1A</sub> receptor agonist.

25

30

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/EP 01/12686

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K31/00 A61K31/496 A61P29/00 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, CHEM ABS Data, WPI Data, PAJ, EPO-Internal, EMBASE, BIOSIS, PASCAL, PHARMAPROJECTS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	EP 0 722 941 A (ELI LILLY AND COMPANY) 24 July 1996 (1996-07-24)  abstract page 2, line 20 - line 31 page 10, line 23 page 100, line 40 claim 18 ----	1,5,10 6
X	EP 0 814 084 A (ELI LILLY AND COMPANY) 29 December 1997 (1997-12-29) page 14, line 32 - line 33 page 19, line 5 ----	1,5,10 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 April 2002

15/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL-2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Gac, G

## INTERNATIONAL SEARCH REPORT

In - ional Application No

PCT/EP 01/12686

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 736 525 A (MERCK PATENT) 9 October 1996 (1996-10-09) cited in the application	5,10
Y	the whole document, especially page 2 lines 3-37, 50-58; page 3 lines 1-10; page 5 line 19 ----	1-4,6
Y	WO 98 14433 A (PFIZER INC.) 9 April 1998 (1998-04-09) page 1, line 7 - line 13 page 18, line 22 - line 29 page 19 ----	1
X	US 5 532 241 A (BÖTTCHER ET AL.) 2 July 1996 (1996-07-02)	5,10
Y	the whole document, especially column 1 lines 5-47, column 7 line 35, column 11 example 4 ----	1-3,6
Y	GB 2 222 768 A (NATIONAL RESEARCH DEVEELOPMENT CORPORATION) 21 March 1990 (1990-03-21) page 2, line 23 - line 28 page 3, line 25 - line 27 page 4 lines 4-8, 14-24 page 5, line 2 - line 5 page 6, line 17 - line 28 page 7, line 1 - line 20 ----	1-4
Y	REDILLAS C ET AL: "Prophylactic pharmacological treatment of chronic daily headache." HEADACHE, (2000 FEB) 40 (2) 83-102. REF: 92, XP001066261 page 85, right-hand column -page 87 page 91, right-hand column ----	1
Y	US 5 578 612 A (J. E. MACOR ET AL.) 26 November 1996 (1996-11-26) abstract column 19, line 31 - line 65 ----	1,6
Y	US 5 589 511 A (J. W. YOUNG ET AL.) 31 December 1996 (1996-12-31) abstract ----	1
Y	US 5 434 174 A (J. S. GIDDA ET AL.) 18 July 1995 (1995-07-18) abstract ----	6
		-/-

## INTERNATIONAL SEARCH REPORT

In — onal Application No

PCT/EP 01/12686

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WANG Y X ET AL: "Antinociceptive properties of fenfluramine, a serotonin reuptake inhibitor, in a rat model of neuropathy." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1999 DEC) 291 (3) 1008-16. ' XP008001941 the whole document ----	1
P,X	WO 00 72832 A (MERCK PATENT) 7 December 2000 (2000-12-07) the whole document, especially abstract and page 1 ----	1-3,5,10
P,X	WO 00 71549 A (KNOLL AG) 30 November 2000 (2000-11-30) page 1, line 1 - line 15 page 22 lines 2,3,26-29 -----	1,5,10

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1,5,10 relate to compounds defined by reference to desirable properties, namely "combined selective serotonin (5-HT) reuptake inhibitors and 5-HT 1A receptor agonists".

The claims cover all compounds having these properties whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in claims 2-4 as well as on the general inventive concept underlying the application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12686

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 722941	A	24-07-1996		US 5576321 A AU 718875 B2 AU 4651696 A BR 9607077 A CA 2210220 A1 CZ 9702207 A3 EP 0722941 A2 FI 973024 A HU 9901099 A2 JP 10512861 T NO 973281 A NZ 301161 A PL 321851 A1 TR 9700644 T1 US 6172073 B1 WO 9622290 A1 US 5741789 A US 5627196 A US 5614523 A US 5789402 A	19-11-1996 20-04-2000 07-08-1996 18-11-1997 25-07-1996 18-02-1998 24-07-1996 16-07-1997 28-07-1999 08-12-1998 08-09-1997 28-10-1999 22-12-1997 21-01-1998 09-01-2001 25-07-1996 21-04-1998 06-05-1997 25-03-1997 04-08-1998
EP 814084	A	29-12-1997		AT 203990 T AU 3401797 A CA 2257962 A1 DE 69706000 D1 DK 814084 T3 EP 0814084 A1 ES 2160894 T3 JP 2000513358 T PT 814084 T WO 9748698 A1 US 5912256 A	15-08-2001 07-01-1998 24-12-1997 13-09-2001 08-10-2001 29-12-1997 16-11-2001 10-10-2000 30-11-2001 24-12-1997 15-06-1999
EP 736525	A	09-10-1996		DE 19512639 A1 AT 194595 T AU 709708 B2 AU 5040896 A BR 9601275 A CA 2173418 A1 CN 1137036 A ,B CZ 9600964 A3 DE 59605568 D1 DK 736525 T3 EP 0736525 A1 ES 2150039 T3 GR 3034514 T3 HU 9600876 A2 JP 9151174 A NO 961346 A PL 313632 A1 PT 736525 T RU 2168508 C2 SI 736525 T1 SK 40396 A3 TR 970156 A2 US 6310068 B1 ZA 9602768 A	10-10-1996 15-07-2000 02-09-1999 17-10-1996 13-01-1998 06-10-1996 04-12-1996 16-10-1996 17-08-2000 30-10-2000 09-10-1996 16-11-2000 29-12-2000 28-09-1998 10-06-1997 07-10-1996 14-10-1996 29-12-2000 10-06-2001 28-02-2001 06-11-1996 21-03-1997 30-10-2001 13-11-1996

## INTERNATIONAL SEARCH REPORT

International Application No

WO/EP 01/12686

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9814433	A 09-04-1998		AP 769 A AU 732451 B2 AU 3951497 A BG 103297 A BR 9713239 A CN 1329002 A CN 1231661 A EP 0929528 A1 HR 970540 A1 WO 9814433 A1 JP 2000503679 T JP 3121355 B2 NO 991525 A PL 332629 A1 SK 41099 A3 TR 9900660 T2 ZA 9708703 A	30-09-1999 26-04-2001 24-04-1998 30-11-1999 04-04-2000 02-01-2002 13-10-1999 21-07-1999 31-08-1998 09-04-1998 28-03-2000 25-12-2000 28-05-1999 27-09-1999 12-09-2000 21-07-1999 30-03-1999
US 5532241	A 02-07-1996		DE 4333254 A1 AT 153663 T AU 679774 B2 AU 7424494 A BR 1100891 A3 CA 2133152 A1 CN 1106811 A , B CZ 9402370 A3 DE 59402902 D1 DK 648767 T3 EP 0648767 A1 ES 2105454 T3 GR 3024551 T3 HU 71833 A2 JP 7149762 A NO 943616 A PL 305216 A1 RU 2132848 C1 SK 118494 A3 ZA 9407622 A	06-04-1995 15-06-1997 10-07-1997 13-04-1995 06-06-2000 31-03-1995 16-08-1995 12-04-1995 03-07-1997 22-12-1997 19-04-1995 16-10-1997 31-12-1997 28-02-1996 13-06-1995 31-03-1995 03-04-1995 10-07-1999 10-05-1995 16-05-1995
GB 2222768	A 21-03-1990		NONE	
US 5578612	A 26-11-1996		CA 2178161 A1 EP 0747353 A2 JP 2957476 B2 JP 8333363 A US 5545644 A US 5559129 A US 5559246 A US 5607951 A AP 486 A AU 689469 B2 AU 6436094 A BG 61898 B1 BG 100093 A BR 9406435 A CA 2161533 A1 CN 1121689 A CZ 9502802 A3	07-12-1996 11-12-1996 04-10-1999 17-12-1996 13-08-1996 24-09-1996 24-09-1996 04-03-1997 16-04-1996 02-04-1998 21-11-1994 30-09-1998 30-04-1996 09-01-1996 10-11-1994 01-05-1996 17-04-1996

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/12686

Patent document cited in search report	Publication date		Patent family member(s)	Publication date	
US 5578612	A		EP 0696194 A1 HU 73670 A2 WO 9425023 A1 IL 109376 A JP 2922307 B2 JP 8504829 T NO 954287 A NZ 263614 A OA 10189 A PL 311266 A1 RU 2132683 C1 SG 43951 A1 SK 133295 A3 ZA 9402805 A AU 651637 B2 BG 61975 B1 BG 97632 A BR 9106978 A DE 69127468 D1 DE 69127468 T2 DK 592438 T3 EP 0592438 A1 FI 931667 A GR 3025087 T3 KR 179053 B1 NO 305121 B1 NO 985607 A PL 168919 B1 PL 170330 B1 PL 169987 B1 RO 111767 B1 RU 2095360 C1 AT 157361 T	14-02-1996 30-09-1996 10-11-1994 31-10-2000 19-07-1999 28-05-1996 26-10-1995 26-02-1998 18-12-1996 05-02-1996 10-07-1999 14-11-1997 08-01-1997 23-10-1995 28-07-1994 30-11-1998 31-03-1994 28-09-1993 02-10-1997 02-01-1998 29-09-1997 20-04-1994 14-04-1993 30-01-1998 20-03-1999 06-04-1999 01-12-1998 31-05-1996 29-11-1996 30-09-1996 30-01-1997 10-11-1997 15-09-1997	14-02-1996 30-09-1996 10-11-1994 31-10-2000 19-07-1999 28-05-1996 26-10-1995 26-02-1998 18-12-1996 05-02-1996 10-07-1999 14-11-1997 08-01-1997 23-10-1995 28-07-1994 30-11-1998 31-03-1994 28-09-1993 02-10-1997 02-01-1998 29-09-1997 20-04-1994 14-04-1993 30-01-1998 20-03-1999 06-04-1999 01-12-1998 31-05-1996 29-11-1996 30-09-1996 30-01-1997 10-11-1997 15-09-1997
US 5589511	A	31-12-1996	US 5104899 A AU 2287495 A WO 9528152 A1 AU 1373692 A AU 1891797 A CA 2123704 A1 EP 0612242 A1 JP 7500812 T WO 9309769 A1	14-04-1992 10-11-1995 26-10-1995 15-06-1993 19-06-1997 27-05-1993 31-08-1994 26-01-1995 27-05-1993	
US 5434174	A	18-07-1995	AT 206918 T AU 4199393 A CA 2100399 A1 CN 1111986 A , B CZ 9301371 A3 DE 69330926 D1 DK 579507 T3 EP 0579507 A1 ES 2162808 T3 HU 68727 A2 IL 106307 A JP 6166620 A MX 9304205 A1 NO 932547 A	15-11-2001 20-01-1994 18-01-1994 22-11-1995 16-11-1994 22-11-2001 12-11-2001 19-01-1994 16-01-2002 28-07-1995 10-06-1997 14-06-1994 31-01-1995 18-01-1994	

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 01/12686

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 5434174	A		PH 30148 A		21-01-1997
			PL 299690 A1		21-03-1994
			RU 2127111 C1		10-03-1999
			ZA 9304969 A		09-01-1995
-----					
WO 0072832	A	07-12-2000	AU 5066300 A		18-12-2000
			WO 0072832 A2		07-12-2000
			EP 1185272 A2		13-03-2002
			NO 20015746 A		26-11-2001
-----					
WO 0071549	A	30-11-2000	AU 5065700 A		12-12-2000
			WO 0071549 A1		30-11-2000
			EP 1178993 A1		13-02-2002
			NO 20015667 A		21-01-2002
-----					